No discussion of academic freedom, research integrity, and patient safety could begin with a more disquieting pair of case studies than those of Nancy Olivieri and David Healy. The cumulative impact of the Olivieri and Healy affairs has caused serious self examination within the biomedical research community. The first part of the essay analyses these recent academic scandals. The two case studies are then placed in their historical context—that context being the transformation of the norms of science through increasingly close ties between research universities and the corporate world. After a literature survey of the ways in which corporate sponsorship has biased the results of clinical drug trials, two different strategies to mitigate this problem are identified and assessed: a regulatory approach, which focuses on managing risks associated with industry funding of university research, and a more radical approach, the sequestration thesis, which counsels the outright elimination of corporate sponsorship. The reformist approach is criticised and the radical approach defended.
- Olivieri/Apotex affair
- David Healy
- biomedical conflicts of interest
- research ethics
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Disclaimer: The author has not been funded by any drug company. He has appeared at three press conferences with Nancy Olivieri, at which his (unpaid) role was to analyse and evaluate the ethical issues raised by her dispute with Apotex, the Hospital for Sick Children, and the University of Toronto.
Arthur Schafer is Professor of Philosophy at the University of Manitoba and Director of the Centre for Professional and Applied Ethics.
Other content recommended for you
- The Olivieri debacle: where were the heroes of bioethics?
- Institutional conflict of interest: attempting to crack the deferiprone mystery
- Introduction to The Olivieri symposium
- The Drug Trial: Nancy Olivieri and the Science Scandal that Rocked the Hospital for Sick Children
- Working with the private sector: the need for institutional guidelines
- Report clears researcher who broke drug company agreement
- Thalassaemia major: the murky story of deferiprone
- Improving researchers’ conflict of interest declarations
- Institutional addiction to tobacco
- Making the prices of new drugs fairer